Shire Viropharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

VPHM 0.0000
price chart
Shire Buys ViroPharma for $4.2 Billion to Add Orphan Drug
11 (Bloomberg) -- Shire Plc agreed to buy ViroPharma Inc. for about $4.2 billion to gain treatments for rare diseases and ease dependence on its best-selling Vyvanse pill for attention deficit hyperactivity disorder.
Shire Buys ViroPharma for $4.2 Billion  Wall Street Journal
Shire to Acquire ViroPharma
Related articles »  
Shire makes yet another move on its local office space
Shire looked at several options and criteria before making this decision, Fisher said. “We wanted to bring everyone together under one roof,” she said.
$4.2 billion deal gives ViroPharma execs huge paydays
Shire's $4.2 billion acquisition of ViroPharma last month generated a huge payday for ViroPharma's top executives and board members.
Shire nears completion of $4.2B ViroPharma deal
U.S.-traded shares of Shire fell 2.5 percent, or $3.72, to $146.24 in morning trading Friday, while broader trading indexes dropped about 1 percent.
Related articles »  
ViroPharma attracted interest from Sanofi, Shire: report
ViroPharma Inc VPHM.O, a drug maker that specializes in rare diseases, has attracted interest from Sanofi SA (SASY.PA) and Shire PLC (SHP.L), Bloomberg reported on Friday, pushing shares of the company up 24 percent. Reuters reported in June that the ...
ViroPharma Said to Hire Goldman Amid Sanofi Interest  Bloomberg
Viropharma Explores Possible Sale After Unsolicited Offer, Shares Soar  ValueWalk
Related articles »  
Inside the deal: Shire's $4.2B acquisition of ViroPharma
While a half-dozen companies kicked ViroPharma's tires this summer, only one ended up making an offer to buy the company.
ViroPharma surges, Shire settles as investors digest $4.2 billion merger
The 25% boost in ViroPharma Inc.'s share price stayed steady but support for Shire plc started to slide toward the breakeven point in Monday morning trades as investors digested the prospects of a merger between the two biotechnology companies.
Shire waives condition for ViroPharma acquisition
Shire said Wednesday it has waived the Office of Fair Trading approval condition that was part of its previously announced $50 per share tender offer for all of the outstanding shares of ViroPharma Inc. The London-based Office of Fair Trading [OFT] is ...
Related articles »  
Shire, ViroPharma, Auxilium mark Rare Disease Day
Auxilium Pharmaceuticals Inc., ViroPharma and Shire are all teaming up with the National Organization for Rare Disorders (NORD) and other organizations to observe Rare Disease Day on Wednesday.
Shire extends tender offer for ViroPharma stock
Shire has extended its previously announced tender offer for all of the outstanding common shares of ViroPharma until midnight on Jan. 9. All of the other terms and conditions of the $50 per share tender offer remain unchanged.
Related articles »